

# Roundtable 4: The Economics of Rare Disease Drug Development

- \* **Moderator: Mark McClellan, The Brookings Institution**
- \* **Panelists: Mark Trusheim, MIT; Bruce Quinn, Foley Hoag; Chris Milne, Center for the Study of Drug Development, Tufts University Medical School; Amber Jessup, Health and Human Services**